Toxicology | Acute Renal Failure | Renal & Gastrointestinal Problems in Critical Care | Renal Pharmacology
Evaluation of the potential adverse effects associated with calcium carbonate precipitate during continuous veno-venous hemofiltration (CVVH)
D Pantaleone, J McKee, B Brooks, J Daller, J Gass, P Zieske, P Mussi, B Moreaux*
*Corresponding author: B Moreaux
Baxter Healthcare Corporation, Braine L'Alleud, Belgium
F1000Posters 2012, 3: 235 (poster) [English]
Poster [1.14 MB]
Presented at
32nd International Symposium on Intensive Care and Emergency Medicine (ISICEM) 2012,
20 - 23 Mar 2012, P365
This study evaluated the potential adverse effects associated with exposure to calcium carbonate precipitate in Accusol 35 Solution (Accusol 35) during continuous veno-venous hemofiltration (CVVH).
CVVH performed on anesthetized dogs for 6 hours, using Accusol 35 containing visible and sub-visible particles 36-times higher than the maximum concentration specified in the European Pharmacopoeia (EP), resulted in no adverse effects on cardiovasular parameters, blood gases and electrolytes, and lung histology, as compared with Accusol 35 containing no visible particles and sub-visible particles that were within EP specification.
All authors are employees of Baxter Healthcare Corporation.
Please note that most posters on this site present work that is preliminary in nature and has not been peer reviewed.
This poster is open access subject to the CC BY-NC Creative Commons 3.0 License
